Drug Profile
PF 3475952
Alternative Names: PF-03475952; PF-3475952Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action CD44 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer metastases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer-metastases(Adjuvant therapy) in USA (Parenteral)
- 03 Oct 2008 Discontinued - Phase-I for Rheumatoid arthritis in USA (unspecified route)